UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Limiting cumulative HIV viremia copy years by early treatment reduces risk of AIDS and death

Olson, A; Walker, AS; Suthar, AB; Sabin, C; Bucher, H; Jarriin, I; Moreno, S; ... Ford, D; + view all (2016) Limiting cumulative HIV viremia copy years by early treatment reduces risk of AIDS and death. Journal of Acquired Immune Deficiency Syndromes , 73 (1) pp. 100-108. 10.1097/QAI.0000000000001029. Green open access

[img]
Preview
Text
Olson.Walker.pdf - Published version

Download (327kB) | Preview

Abstract

BACKGROUND: Viremia copy-years (VCY), a time-updated measure of cumulative HIV exposure predicts AIDS/death; although its utility in deciding when to start combination antiretroviral therapy (cART) remains unclear. We aimed to assess the impact of initiating versus deferring cART on risk of AIDS/death by levels of VCY both independent of and within CD4 cell count strata ≥500 cells/mm3. / METHODS: Using CASCADE data, we created a series of nested –‘trials’ corresponding to consecutive months for individuals ≥16 years at seroconversion (SC) after 1995 who were cART-naïve and AIDS-free. Pooling across all ‘trials’, time to AIDS/death by CD4 and VCY strata was compared in those initiating vs. deferring cART using Cox models adjusted for: country, sex, risk group, SC year, age, time since last HIV-RNA, and current CD4, VCY, HIV-RNA, and mean number of previous CD4/HIV-RNA measurements/year. / RESULTS: Of 9,353 individuals, 5312 (57%) initiated cART and 486 (5%) acquired AIDS/died. Pooling CD4 strata, risk of AIDS/death associated with initiating vs. deferring cART reduced as VCY increased. In patients with high CD4 cell counts, ≥500 cells/mm3, there was a trend for a greater reduction for those initiating vs. deferring with increasing VCY (p = 0.09) with the largest benefit in the VCY ≥ 100,000 copy-years/mL group (HR (95% CI)= 0.41 (0.19, 0.87)). / CONCLUSIONS: For individuals with CD4 ≥500 cells/mm3, limiting the cumulative HIV burden to <100,000 copy-years/mL through cART may reduce the risk of AIDS/death, supporting recent START trial results suggesting immediate cART initiation vs. waiting until CD4 <350 cells/mm3.

Type: Article
Title: Limiting cumulative HIV viremia copy years by early treatment reduces risk of AIDS and death
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/QAI.0000000000001029
Publisher version: http://dx.doi.org/10.1097/QAI.0000000000001029
Language: English
Additional information: This is a non-final version of an article to be published in final form in the Journal of Acquired Immune Deficiency Syndromes.
Keywords: Viremia copy-years, seroconverters, when to start, cART initiation, CD4 cell count, HIV-RNA
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health > Infection and Population Health
URI: https://discovery.ucl.ac.uk/id/eprint/1477391
Downloads since deposit
40Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item